DNA Ginkgo Bioworks Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DNA matters now
Ginkgo Bioworks Holdings, Inc. (DNA) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.09 with -6.58% on the session and $593.8M in market capitalization; recent performance reads 1-month +24.59% and YTD +10.35%.
The latest financial table shown here is Q1 2026, with revenue of $19.5M, net income of $-82.6M, and EPS of $-1.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.6%.
The latest indexable market news headline is "A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Sell with a median target of $7.50; recent insider activity includes SLOAN HARRY filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.23
P/S
4.24
EV/EBITDA
-4.11
DCF Value
$-32.73
FCF Yield
-30.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.0%
Operating Margin
-210.7%
Net Margin
-215.4%
ROE
-57.3%
ROA
-29.5%
ROIC
-31.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.5M | $-82.6M | $-1.39 |
| Q4 2025 | $33.4M | $-80.8M | $-1.43 |
| FY 2025 | $170.2M | $-312.8M | $-5.64 |
| Q3 2025 | $38.8M | $-80.8M | $-1.45 |
Analyst Ratings
Consensus
Sell
Target (Consensus)
$7.84
Target (Median)
$7.50
Target Range
$4.35 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.80
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.